Trial Profile
A phase I pilot, pharmacokinetics and safety/tolerability study of Renown's sub-lingual apomorphine spray
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- 03 Apr 2017 New trial record
- 07 Mar 2017 Results published in the Renown Pharma media release.